Lunit Cancer Screening

Don’t just hear about breast imaging AI at EUSOBI 2026 - experience it. Join Lunit’s hands-on workshops to explore real-world clinical cases with expert guidance, learn from clinical leaders at our booth, or book a live workflow demo with our team to discuss your needs. 📆 October 1-3, 2026 📍Lunit booth R05 Connect with us: https://lnkd.in/gUvyRv5i/?utm_campaign=Supreme-LunitHQ&utm_source=linkedin&utm_medium=paid&utm_id=772012016&hsa_acc=508739372&hsa_cam=772012016&hsa_grp=904501566&hsa_ad=1626223676&hsa_net=linkedin&hsa_ver=3

Heading to EUSOBI 2026? Join Lunit’s hands-on workshops to experience AI in breast imaging firsthand, explore clinical cases, and see our solutions in action: 📆 Session 1: Day 2, October 2nd, 3:10 - 4:00 pm 📆 Session 2: Day 3, October 3rd, 12:30 - 1:15 pm 📍 Location: Room 0.8 / MECC, ground floor Want a closer look? Book a 1:1 meeting and live demo with our team.

Quel est l’impact réel de l’IA en mammographie au quotidien ? Aux JFR 2026, le Dr Aurélie Jalaguier du Centre de Sénologie Mermoz partagera son expérience concrète de l’IA Lunit en sénologie, avec des cas cliniques à l’appui. Au programme : intégration au workflow, apports au diagnostic et perception des patientes. 📅 Samedi 10 octobre | 15h35-15h50 📍 Forum IA Rejoignez-nous pour « L’IA en dépistage du cancer du sein : parlons-en ! »

Attending EUSOBI 2026? Connect with Lunit’s breast imaging AI experts to discuss your clinical needs, explore our latest solutions, and discover how AI can support your breast imaging workflow. 📆 October 1-3, 2026 📍Lunit booth R05 Meet the team: https://lnkd.in/gnuWVHb6/?utm_campaign=Supreme-LunitHQ&utm_source=linkedin&utm_medium=paid&utm_id=772012016&hsa_acc=508739372&hsa_cam=772012016&hsa_grp=904501566&hsa_ad=1626381126&hsa_net=linkedin&hsa_ver=3

Lunit sera présent aux JFR 2026 à Paris ! Venez rencontrer notre équipe et découvrir comment l’IA de Lunit accompagne les radiologues dans le dépistage du cancer du sein. 📅 8-11 octobre 2026 📍 Stand Lunit #FIA-4, Palais des Congrès de Paris - Niveau 3, Hall Havane Prenez rendez-vous avec notre équipe et venez nous rencontrer aux JFR 2026.

In extremely dense breasts, how do you decide whether to recall or not? 🌫️ Dense tissue doesn't only hide cancer. It can also blur the boundary between normal and abnormal, making recall decisions more challenging as density increases. That's where a second set of eyes can help. 👀 A Breast Cancer Research study put Lunit INSIGHT® MMG to the test in a large Korean screening population where 87.1% of women had dense breasts, including 41.6% with extremely dense breasts. In women with extremely dense breasts, standalone AI performance: ➜ Specificity: 91.5% (AI) vs. 74.5% (radiologists) ➜ PPV: 1.2% vs. 0.4% ➜ Recall rate: 8.6% vs. 25.5% ➜ Comparable cancer detection performance While recall rates in this study population were higher than those typically reported in many screening programs, INSIGHT MMG demonstrated substantially higher specificity and comparable cancer detection performance in women with extremely dense breasts. If AI is going to add value, it should be where uncertainty is greatest. 🎯 This study suggests it can. Read the full study here: https://lnkd.in/dctcDyzV/?utm_campaign=Supreme-LunitInternational&utm_source=linkedin&utm_medium=paid&utm_id=845718426&hsa_acc=508739372&hsa_cam=845718426&hsa_grp=855926356&hsa_ad=1623770196&hsa_net=linkedin&hsa_ver=3 #BreastCancer #BreastImaging #RadiologyAI #CancerScreening